Table 1

The demographic and clinical profile of patients with cyclic vomiting syndrome and cannabinoid hyperemesis syndrome at Texas Tech University Health Sciences Center

CharacteristicsCHS
n=18
CVS
n=27
P value
Median age (IQR)35 (26, 43)41 (33, 54)0.86
Race
 White6 (33.3)9 (33.3)1.00
 Black1 (5.6)0 (0)0.40
 Hispanic10 (55.6)18 (66.7)0.54
 Asian1 (5.6)0 (0)0.40
Median years of symptoms before diagnosis4.5 (2.8, 10.8)3 (2, 6)0.76
Etiology
 Cannabis only5 (27.8)0 (0)<0.001
 Stress13 (72.2)23 (85.2)<0.448
 Migraine0 (0)2 (7.4)<0.001
 Diabetes mellitus0 (0)1 (3.7)<0.001
 Unknown0 (0)1 (3.7)<0.001
Current treatment0.79
 None1 (5.6)2 (7.4)1.00
 Amitriptyline8 (44.4)13 (48.1)1.00
 Doxepin3 (16.7)2 (7.4)0.36
 Multiple6 (33.3)7 (25.9)0.74
 Nortriptyline0 (0)1 (3.7)1.00
 Dicyclomine0 (0)1 (3.7)1.00
 Unknown0 (0)1 (3.7)1.00
Currently on treatment*17 (94.4)22 (81.5)0.37
Improvement in symptoms on treatment18 (100)27 (100)1.00
Mean improvement in pain scale (%)70800.8
Decreased hospitalizations17 (94.4)27 (100)0.40
Symptoms manageable17 (94.4)27 (100)0.40
Last hospitalization (y)
 <17 (38.9)11 (40.7)1.00
 1–310 (55.5)15 (55.5)1.00
 4–61 (5.6)1 (3.7)1.00
Currently on narcotics4 (22.3)1 (3.7)0.14
Stress reduced14 (77.8)23 (85.2)0.69
On counseling6 (33.3)9 (33.3)1.00
Returned to social activities13 (72.2)24 (88.9)0.24
Happier than before16 (88.9)27 (100)0.16
  • *All 18 patients (100%) in the CHS group either stopped or decreased the marijuana intake.

  • CHS, cannabinoid hyperemesis syndrome; CVS, cyclic vomiting syndrome.